Centiva Capital, LP Iovance Biotherapeutics, Inc. Transaction History

Centiva Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $83,717 - $192,694	11,030 New	11,030 $163,000
Q2 2021 Aug 16, 2021	SELL	$16.33 - $33.07 $161,618 - $327,293	-9,897 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$28.67 - $52.59 $140,310 - $257,375	4,894 Added 97.82%	9,897 $313,000
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $140,284 - $251,450	5,003 New	5,003 $232,000
Q4 2019 Feb 14, 2020	SELL	$17.95 - $29.41 $257,420 - $421,768	-14,341 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$17.99 - $26.0 $257,994 - $372,866	14,341 New	14,341 $261,000

320

238M

1.27M

1.68M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.74B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.